# Firy Inc.: financial statements, quarterly

FIRY · NYSE · CIK 1801661 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/firy.md) · [Financials](/companies/firy/financials.md) · [Filings](/companies/firy/filings.md) · [Insiders](/companies/firy/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/firy/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [36.4](/filings/0001801661-24-000141.md) | [31.1 d](/filings/0001801661-25-000050.md) | [25.2](/filings/0001801661-25-000070.md) | [25.3](/filings/0001801661-25-000071.md) | [24.6](/filings/0001801661-25-000072.md) | [17.8 d](/filings/0001801661-26-000020.md) | [21.9](/filings/0001801661-26-000031.md) | [25.2](/filings/0001801661-26-000097.md) | [27.4](/filings/0001801661-25-000072.md) | [30.0 d](/filings/0001801661-26-000020.md) | [29.1](/filings/0001801661-26-000031.md) | [31.0](/filings/0001801661-26-000097.md) |
| Cost of revenue | $m | [3.7](/filings/0001801661-24-000141.md) | [3.5 d](/filings/0001801661-25-000050.md) | [3.5](/filings/0001801661-25-000070.md) | [3.3](/filings/0001801661-25-000071.md) | [3.4](/filings/0001801661-25-000072.md) | [3.2 d](/filings/0001801661-26-000020.md) | [3.0](/filings/0001801661-26-000031.md) | [3.2](/filings/0001801661-26-000097.md) | [3.4](/filings/0001801661-25-000072.md) | [3.5 d](/filings/0001801661-26-000020.md) | [3.6](/filings/0001801661-26-000031.md) | [3.9](/filings/0001801661-26-000097.md) |
| Research and development | $m | [7.9](/filings/0001801661-24-000141.md) | [3.4 d](/filings/0001801661-25-000050.md) | [4.6](/filings/0001801661-25-000070.md) | [4.3](/filings/0001801661-25-000071.md) | [4.7](/filings/0001801661-25-000072.md) | [3.1 d](/filings/0001801661-26-000020.md) | [4.8](/filings/0001801661-26-000031.md) | [4.8](/filings/0001801661-26-000097.md) | [5.4](/filings/0001801661-25-000072.md) | [5.5 d](/filings/0001801661-26-000020.md) | [5.1](/filings/0001801661-26-000031.md) | [6.9](/filings/0001801661-26-000097.md) |
| Operating income | $m | [(31.4)](/filings/0001801661-24-000141.md) | [(20.5) d](/filings/0001801661-25-000050.md) | [(26.9)](/filings/0001801661-25-000070.md) | [25.6](/filings/0001801661-25-000071.md) | [(21.0)](/filings/0001801661-25-000072.md) | [(24.2) d](/filings/0001801661-26-000020.md) | [(15.5)](/filings/0001801661-26-000031.md) | [(16.0)](/filings/0001801661-26-000097.md) | [(16.3)](/filings/0001801661-25-000072.md) | [(16.2) d](/filings/0001801661-26-000020.md) | [(8.8)](/filings/0001801661-26-000031.md) | [(21.6)](/filings/0001801661-26-000097.md) |
| Interest expense | $m | [2.3](/filings/0001628280-23-037874.md) | [14.0 d](/filings/0001801661-24-000100.md) | [3.8](/filings/0001801661-24-000102.md) | [3.8](/filings/0001801661-25-000071.md) | [3.8](/filings/0001801661-25-000072.md) | [3.8 d](/filings/0001801661-26-000020.md) | [3.8](/filings/0001801661-26-000031.md) | [3.8](/filings/0001801661-26-000097.md) | [3.8](/filings/0001801661-25-000072.md) | [3.8 d](/filings/0001801661-26-000020.md) | [3.8](/filings/0001801661-26-000031.md) | [3.9](/filings/0001801661-26-000097.md) |
| Income tax | $m | [0.0](/filings/0001801661-24-000141.md) | [0.0 d](/filings/0001801661-25-000050.md) | [0.0](/filings/0001801661-25-000070.md) | [0.1](/filings/0001801661-25-000071.md) | [0.0](/filings/0001801661-25-000072.md) | [(0.1) d](/filings/0001801661-26-000020.md) | [0.0](/filings/0001801661-26-000031.md) | [(0.0)](/filings/0001801661-26-000097.md) | [0.0](/filings/0001801661-25-000072.md) | [0.0 d](/filings/0001801661-26-000020.md) | [0.1](/filings/0001801661-26-000031.md) | [0.1](/filings/0001801661-26-000097.md) |
| Net income | $m | [(33.5)](/filings/0001801661-24-000141.md) | [(15.5) d](/filings/0001801661-25-000050.md) | [(26.7)](/filings/0001801661-25-000072.md) | [26.0](/filings/0001801661-25-000072.md) | [(21.1)](/filings/0001801661-25-000072.md) | [(25.0) d](/filings/0001801661-26-000020.md) | [(17.1)](/filings/0001801661-26-000097.md) | [(17.9)](/filings/0001801661-26-000097.md) | [(17.4)](/filings/0001801661-25-000072.md) | [(17.9) d](/filings/0001801661-26-000020.md) | [(10.9)](/filings/0001801661-26-000097.md) | [(24.5)](/filings/0001801661-26-000097.md) |
| Diluted EPS | $ per share | [(1.57)](/filings/0001801661-24-000141.md) | not reported | [(1.45)](/filings/0001801661-25-000070.md) | [1.44](/filings/0001801661-25-000071.md) | [(1.20)](/filings/0001801661-25-000072.md) | not reported | [(1.05)](/filings/0001801661-26-000031.md) | [(1.16)](/filings/0001801661-26-000097.md) | [(1.14)](/filings/0001801661-25-000072.md) | not reported | [(0.69)](/filings/0001801661-26-000031.md) | [(1.52)](/filings/0001801661-26-000097.md) |
| Basic EPS | $ per share | [(1.57)](/filings/0001801661-24-000141.md) | not reported | [(1.45)](/filings/0001801661-25-000070.md) | [1.47](/filings/0001801661-25-000071.md) | [(1.20)](/filings/0001801661-25-000072.md) | not reported | [(1.05)](/filings/0001801661-26-000031.md) | [(1.16)](/filings/0001801661-26-000097.md) | [(1.14)](/filings/0001801661-25-000072.md) | not reported | [(0.69)](/filings/0001801661-26-000031.md) | [(1.52)](/filings/0001801661-26-000097.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [330](/filings/0001628280-23-037874.md) | [302](/filings/0001801661-25-000050.md) | [291](/filings/0001801661-24-000102.md) | [316](/filings/0001801661-24-000104.md) | [301](/filings/0001801661-24-000141.md) | [272](/filings/0001801661-26-000020.md) | [254](/filings/0001801661-25-000070.md) | [229](/filings/0001801661-25-000071.md) | [212](/filings/0001801661-25-000072.md) | [195](/filings/0001801661-26-000097.md) | [185](/filings/0001801661-26-000031.md) | [164](/filings/0001801661-26-000097.md) |
| Current assets | $m | [350](/filings/0001628280-23-037874.md) | [315](/filings/0001801661-25-000050.md) | [312](/filings/0001801661-24-000102.md) | [335](/filings/0001801661-24-000104.md) | [322](/filings/0001801661-24-000141.md) | [303](/filings/0001801661-26-000020.md) | [287](/filings/0001801661-25-000070.md) | [254](/filings/0001801661-25-000071.md) | [233](/filings/0001801661-25-000072.md) | [216](/filings/0001801661-26-000097.md) | [209](/filings/0001801661-26-000031.md) | [189](/filings/0001801661-26-000097.md) |
| Total assets | $m | [428](/filings/0001628280-23-037874.md) | [396](/filings/0001801661-25-000050.md) | [382](/filings/0001801661-24-000102.md) | [403](/filings/0001801661-24-000104.md) | [390](/filings/0001801661-24-000141.md) | [374](/filings/0001801661-26-000020.md) | [360](/filings/0001801661-25-000070.md) | [328](/filings/0001801661-25-000071.md) | [309](/filings/0001801661-25-000072.md) | [293](/filings/0001801661-26-000097.md) | [287](/filings/0001801661-26-000031.md) | [272](/filings/0001801661-26-000097.md) |
| Current liabilities | $m | [64.8](/filings/0001628280-23-037874.md) | [49.9](/filings/0001801661-25-000050.md) | [61.5](/filings/0001801661-24-000102.md) | [52.4](/filings/0001801661-24-000104.md) | [55.5](/filings/0001801661-24-000141.md) | [65.9](/filings/0001801661-26-000020.md) | [67.7](/filings/0001801661-25-000070.md) | [60.9](/filings/0001801661-25-000071.md) | [53.9](/filings/0001801661-25-000072.md) | [181](/filings/0001801661-26-000097.md) | [184](/filings/0001801661-26-000031.md) | [184](/filings/0001801661-26-000097.md) |
| Total liabilities | $m | [200](/filings/0001628280-23-037874.md) | [185](/filings/0001801661-25-000050.md) | [197](/filings/0001801661-24-000102.md) | [188](/filings/0001801661-24-000104.md) | [191](/filings/0001801661-24-000141.md) | [201](/filings/0001801661-26-000020.md) | [203](/filings/0001801661-25-000070.md) | [188](/filings/0001801661-25-000071.md) | [182](/filings/0001801661-25-000072.md) | [182](/filings/0001801661-26-000097.md) | [185](/filings/0001801661-26-000031.md) | [187](/filings/0001801661-26-000097.md) |
| Long-term debt | $m | [124](/filings/0001628280-23-037874.md) | [124](/filings/0001801661-25-000050.md) | [124](/filings/0001801661-24-000102.md) | [125](/filings/0001801661-24-000104.md) | [125](/filings/0001801661-24-000141.md) | [126](/filings/0001801661-26-000020.md) | [126](/filings/0001801661-25-000070.md) | [127](/filings/0001801661-25-000071.md) | [127](/filings/0001801661-25-000072.md) | [0.0](/filings/0001801661-26-000097.md) | [0.0](/filings/0001801661-26-000031.md) | [0.0](/filings/0001801661-26-000097.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001801661-26-000020.md) | not reported | not reported | not reported | [128](/filings/0001801661-26-000097.md) | [128](/filings/0001801661-26-000031.md) | [129](/filings/0001801661-26-000097.md) |
| Shareholders' equity | $m | [228](/filings/0001801661-24-000141.md) | [210](/filings/0001801661-26-000020.md) | [186](/filings/0001801661-25-000072.md) | [215](/filings/0001801661-25-000072.md) | [199](/filings/0001801661-25-000072.md) | [173](/filings/0001801661-26-000097.md) | [157](/filings/0001801661-26-000097.md) | [140](/filings/0001801661-26-000097.md) | [127](/filings/0001801661-25-000072.md) | [112](/filings/0001801661-26-000097.md) | [102](/filings/0001801661-26-000097.md) | [84.5](/filings/0001801661-26-000097.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(18.4) d](/filings/0001801661-24-000141.md) | [(12.3) d](/filings/0001801661-25-000050.md) | [(4.4)](/filings/0001801661-25-000070.md) | [27.8 d](/filings/0001801661-25-000071.md) | [(11.0) d](/filings/0001801661-25-000072.md) | [(19.5) d](/filings/0001801661-26-000020.md) | [(10.9)](/filings/0001801661-26-000031.md) | [(20.8) d](/filings/0001801661-26-000097.md) | [(24.5) d](/filings/0001801661-25-000072.md) | [(12.7) d](/filings/0001801661-26-000020.md) | [(6.7)](/filings/0001801661-26-000031.md) | [(17.9) d](/filings/0001801661-26-000097.md) |
| Capital expenditure | $m | [0.5 d](/filings/0001801661-24-000141.md) | [1.2 d](/filings/0001801661-25-000050.md) | [0.5](/filings/0001801661-25-000070.md) | [0.4 d](/filings/0001801661-25-000071.md) | [0.4 d](/filings/0001801661-25-000072.md) | [(0.6) d](/filings/0001801661-26-000020.md) | [1.2](/filings/0001801661-26-000031.md) | [0.6 d](/filings/0001801661-26-000097.md) | [0.3 d](/filings/0001801661-25-000072.md) | [(0.7) d](/filings/0001801661-26-000020.md) | [0.4](/filings/0001801661-26-000031.md) | [(0.3) d](/filings/0001801661-26-000097.md) |
| Share repurchases | $m | [0.0 d](/filings/0001801661-24-000141.md) | [13.0 d](/filings/0001801661-25-000050.md) | [7.0](/filings/0001801661-25-000070.md) | [3.8 d](/filings/0001801661-25-000071.md) | [0.1 d](/filings/0001801661-25-000072.md) | [8.4 d](/filings/0001801661-26-000020.md) | [4.7](/filings/0001801661-26-000031.md) | [3.0 d](/filings/0001801661-26-000097.md) | [0.0 d](/filings/0001801661-25-000072.md) | [1.5 d](/filings/0001801661-26-000020.md) | [0.0](/filings/0001801661-26-000031.md) | [0.0 d](/filings/0001801661-26-000097.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets, us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [20.7](/filings/0001628280-23-037874.md) | [20.9](/filings/0001801661-24-000102.md) | [21.1](/filings/0001801661-24-000104.md) | [21.3](/filings/0001801661-24-000141.md) | [18.5](/filings/0001801661-25-000070.md) | [18.1](/filings/0001801661-25-000071.md) | [17.5](/filings/0001801661-25-000072.md) | [16.3](/filings/0001801661-26-000031.md) | [15.5](/filings/0001801661-26-000097.md) | [15.3](/filings/0001801661-25-000072.md) | [15.8](/filings/0001801661-26-000031.md) | [16.1](/filings/0001801661-26-000097.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.